Ganga Pharmaceuticals Ltd
Incorporated in 1989, Ganga Pharmaceuticals Ltd manufactures & trades in Pharmaceuticals & allied products (Ayurveda)[1]
- Market Cap ₹ 7.06 Cr.
- Current Price ₹ 14.6
- High / Low ₹ 27.1 / 9.25
- Stock P/E 88.2
- Book Value ₹ 14.7
- Dividend Yield 0.00 %
- ROCE 3.18 %
- ROE 1.13 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.99 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -2.46% over past five years.
- Company has a low return on equity of 0.91% over last 3 years.
- Promoter holding has decreased over last 3 years: -10.7%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2.66 | 2.44 | 2.45 | 2.63 | 2.73 | 3.18 | 2.99 | 2.27 | 2.32 | 2.47 | 2.74 | 2.64 | |
2.43 | 2.19 | 2.15 | 2.32 | 2.41 | 2.76 | 2.61 | 2.24 | 2.28 | 2.47 | 2.69 | 2.76 | |
Operating Profit | 0.23 | 0.25 | 0.30 | 0.31 | 0.32 | 0.42 | 0.38 | 0.03 | 0.04 | -0.00 | 0.05 | -0.12 |
OPM % | 8.65% | 10.25% | 12.24% | 11.79% | 11.72% | 13.21% | 12.71% | 1.32% | 1.72% | -0.00% | 1.82% | -4.55% |
0.15 | 0.17 | 0.14 | 0.16 | 0.15 | 0.14 | 0.17 | 0.25 | 0.26 | 0.30 | 0.24 | 0.44 | |
Interest | 0.30 | 0.33 | 0.33 | 0.32 | 0.28 | 0.25 | 0.24 | 0.19 | 0.19 | 0.19 | 0.18 | 0.18 |
Depreciation | 0.03 | 0.04 | 0.04 | 0.04 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | 0.05 | 0.05 |
Profit before tax | 0.05 | 0.05 | 0.07 | 0.11 | 0.13 | 0.26 | 0.26 | 0.04 | 0.06 | 0.05 | 0.06 | 0.09 |
Tax % | 40.00% | 40.00% | 28.57% | 27.27% | 23.08% | 30.77% | 23.08% | 50.00% | 16.67% | 40.00% | 33.33% | 11.11% |
0.03 | 0.03 | 0.05 | 0.07 | 0.09 | 0.19 | 0.19 | 0.02 | 0.04 | 0.04 | 0.05 | 0.08 | |
EPS in Rs | 0.13 | 0.13 | 0.12 | 0.17 | 0.22 | 0.47 | 0.47 | 0.05 | 0.10 | 0.10 | 0.10 | 0.17 |
Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 1% |
5 Years: | -2% |
3 Years: | 4% |
TTM: | -4% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | -16% |
3 Years: | 26% |
TTM: | 60% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -41% |
Return on Equity | |
---|---|
10 Years: | 2% |
5 Years: | 1% |
3 Years: | 1% |
Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 2.33 | 2.33 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.84 | 4.84 |
Reserves | 0.28 | 0.31 | 0.74 | 0.81 | 0.91 | 1.09 | 1.29 | 1.31 | 1.35 | 1.39 | 2.21 | 2.29 |
2.07 | 2.14 | 2.19 | 2.14 | 2.05 | 1.87 | 1.47 | 1.73 | 1.93 | 1.83 | 1.36 | 1.42 | |
0.46 | 0.61 | 0.35 | 0.60 | 1.22 | 0.74 | 0.75 | 0.56 | 0.66 | 0.71 | 0.24 | 0.42 | |
Total Liabilities | 5.14 | 5.39 | 7.34 | 7.61 | 8.24 | 7.76 | 7.57 | 7.66 | 8.00 | 7.99 | 8.65 | 8.97 |
0.65 | 0.65 | 0.62 | 0.62 | 0.82 | 0.80 | 0.76 | 0.72 | 0.68 | 0.64 | 0.61 | 0.66 | |
CWIP | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
Investments | 0.05 | 0.05 | 0.50 | -0.00 | -0.00 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | -0.00 |
4.44 | 4.69 | 6.22 | 6.99 | 7.42 | 6.87 | 6.72 | 6.85 | 7.23 | 7.26 | 7.95 | 8.31 | |
Total Assets | 5.14 | 5.39 | 7.34 | 7.61 | 8.24 | 7.76 | 7.57 | 7.66 | 8.00 | 7.99 | 8.65 | 8.97 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.21 | 0.27 | -1.05 | 0.05 | 0.24 | 0.11 | -0.31 | -0.18 | -0.21 | -0.04 | -1.26 | -0.58 | |
-0.23 | -0.18 | -0.83 | 0.62 | -0.14 | 0.28 | 0.37 | 0.28 | 0.19 | 0.49 | 0.13 | 1.18 | |
0.43 | -0.06 | 1.90 | -0.33 | -0.36 | -0.45 | -0.29 | -0.10 | 0.03 | -0.44 | 1.14 | -0.33 | |
Net Cash Flow | -0.01 | 0.03 | 0.02 | 0.33 | -0.26 | -0.05 | -0.22 | -0.00 | 0.01 | 0.01 | -0.00 | 0.27 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 94.68 | 109.20 | 140.04 | 173.48 | 211.25 | 141.18 | 130.62 | 131.85 | 140.02 | 131.52 | 122.55 | 125.81 |
Inventory Days | 312.46 | 288.16 | 374.86 | 385.66 | 358.71 | 341.26 | 296.56 | 332.62 | 330.51 | 347.34 | 362.08 | 353.03 |
Days Payable | 105.08 | 118.01 | 98.65 | 182.50 | 330.39 | 163.21 | 159.69 | 129.52 | 152.32 | 170.73 | 29.20 | 83.77 |
Cash Conversion Cycle | 302.07 | 279.35 | 416.26 | 376.64 | 239.56 | 319.23 | 267.49 | 334.96 | 318.21 | 308.13 | 455.43 | 395.08 |
Working Capital Days | 222.29 | 233.36 | 597.41 | 428.84 | 417.14 | 387.96 | 449.23 | 619.05 | 667.07 | 653.16 | 730.00 | 851.67 |
ROCE % | 7.87% | 8.03% | 6.80% | 6.14% | 5.84% | 7.26% | 7.23% | 3.30% | 3.46% | 3.28% | 3.06% | 3.18% |
Documents
Announcements
-
Non -Exercise Of Option To Convert Of Warrants.
19 Jul - Forfeiture of Rs. 24.5 lakh on 7 lakh unconverted warrants by three allottees.
-
Announcement under Regulation 30 (LODR)-Allotment
17 Jul - Allotted 10.75 lakh equity shares at Rs.14 each on warrant conversion; paid-up capital increased to Rs.5.91 crore.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Jul - Certificate in terms Reg 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 2025
-
Appointment of Company Secretary and Compliance Officer
1 Jul - Appointment of Ms. Priti Bhaiya as Company Secretary & Compliance Officer effective July 1, 2025.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
28 May - Ganga Pharma exempt from Annual Secretarial Compliance Report for FY 2025 due to SME listing and capital criteria.
Annual reports
Concalls
-
May 2024TranscriptNotesPPT
Business Overview:[1]
GPL is engaged in production of quality Ayurvedic Medicines. Apart from manufacturing, the company is also into marketing and distribution of Ayurvedic Medicines